重组Anti-PACT (PKR activating蛋白) / PRKRA抗体[EPR3224] (ab75749)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR3224] to PACT (PKR activating protein) / PRKRA
- Suitable for: WB, IHC-P
- Knockout validated
- Reacts with: Human
Related conjugates and formulations
概述
-
产品名称
Anti-PACT (PKR activating蛋白) / PRKRA抗体[EPR3224]
参阅全部 PACT (PKR activating protein) / PRKRA 一抗 -
描述
兔单克隆抗体[EPR3224] to PACT (PKR activating蛋白) / PRKRA -
宿主
Rabbit -
经测试应用
适用于: WB, IHC-Pmore details
不适用于: Flow Cyt,ICC/IF or IP -
种属反应性
与反应: Human
预测可用于: Mouse, Rat -
免疫原
Synthetic peptide within Human PACT (PKR activating protein)/ PRKRA aa 300-400 (C terminal). The exact sequence is proprietary.
-
阳性对照
- WB: HEK-293T, K562, Jurkat and HepG2 whole cell lysate (ab7900). IHC-P: Human brain tissue.
-
常规说明
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
性能
-
形式
Liquid -
存放说明
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
存储溶液
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, 50% Tissue culture supernatant -
Concentration information loading...
-
纯度
Protein A purified -
克隆
单克隆 -
克隆编号
EPR3224 -
同种型
IgG -
研究领域
相关产品
-
Alternative Versions
-
Isotype control
-
KO cell lines
-
KO cell lysates
-
Positive Controls
-
Recombinant Protein
应用
The Abpromise guarantee
Abpromise™承诺保证使用ab75749于以下的经测试应用
“应用说明”部分 下显示的仅为推荐的起始稀释度;实际最佳的稀释度/浓度应由使用者检定。
应用 | Ab评论 | 说明 |
---|---|---|
WB | ||
IHC-P |
说明 |
---|
WB: 1/1000 - 1/5000. Detects a band of approximately 34 kDa (predicted molecular weight: 34 kDa).
Is unsuitable for Flow Cyt, ICC or IP.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
靶标
-
功能
Activates EIF2AK2/PKR in the absence of double stranded RNA (dsRNA), leading to phosphorylation of EIF2S1/EFI2-alpha and inhibition of translation and induction of apoptosis. Required for siRNA production by DICER1 and for subsequent siRNA-mediated post-transcriptional gene silencing. Does not seem to be required for processing of pre-miRNA to miRNA by DICER1. -
疾病相关
Defects in PRKRA are the cause of dystonia type 16 (DYT16) [MIM:612067]. DYT16 is an early-onset dystonia-parkinsonism disorder. Dystonia is defined by the presence of sustained involuntary muscle contraction, often leading to abnormal postures. DYT16 patients have progressive, generalized dystonia with axial muscle involvement, oro-mandibular (sardonic smile) and laryngeal dystonia and, in some cases, parkinsonian features. -
序列相似性
Belongs to the PRKRA family.
Contains 3 DRBM (double-stranded RNA-binding) domains. -
结构域
Self-association may occur via interactions between DRBM domains as follows: DRBM 1/DRBM 1, DRBM 1/DRBM 2, DRBM 2/DRBM 2 or DRBM 3/DRBM3. -
翻译后修饰
Phosphorylated at Ser-246 in unstressed cells and at Ser-287 in stressed cells. Phosphorylation at Ser-246 appears to be a prerequisite for subsequent phosphorylation at Ser-287. Phosphorylation at Ser-246 and Ser-287 are necessary for activation of EIF2AK2/PKR under conditions of stress. -
细胞定位
Cytoplasm > perinuclear region. - Information by UniProt
-
数据库链接
- Entrez Gene: 8575 Human
- Entrez Gene: 23992 Mouse
- Entrez Gene: 311130 Rat
- Omim: 603424 Human
- SwissProt: O75569 Human
- SwissProt: Q9WTX2 Mouse
- SwissProt: Q4V8C7 Rat
- Unigene: 570274 Human
see all -
别名
- DYT16 antibody
- HSD14 antibody
- Interferon inducible double stranded RNA dependent protein kinase activator A antibody
see all
图片
-
All lanes : Anti-PACT (PKR activating protein) / PRKRA antibody [EPR3224] (ab75749) at 1/1000 dilution
Lane 1 : Wild-type HEK-293T cell lysate
Lane 2 : PRKRA knockout HEK-293T cell lysate
Lane 3 : K-562 cell lysate
Lane 4 : HepG2 cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) at 1/10000 dilution
Predicted band size: 34 kDa
Observed band size: 36 kDa why is the actual band size different from the predicted?Lanes 1-4: Merged signal (red and green). Green - ab75749 observed at 36 kDa. Red - loading control ab8245 observed at 36 kDa.
ab75749 Anti-PACT (PKR activating protein) / PRKRA antibody [EPR3224] was shown to specifically react with PACT in wild-type HEK-293T cells. Loss of signal was observed when knockout cell line ab266806 (knockout cell lysate ab258141) was used. Wild-type and PACT knockout samples were subjected to SDS-PAGE. ab75749 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated at room temperature for 2. 5 hours at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PACT (PKR activating protein) / PRKRA antibody [EPR3224] (ab75749)
ab75749 at 1/100 dilution staining PACT (PKR activating protein) / PRKRA in paraffin-embedded human brain tissue.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
-
Lane 1: Wild-type HAP1 cell lysate (20 µg)
Lane 2: PACT (PKR activating protein)/PRKRA knockout HAP1 cell lysate (20 µg)
Lane 3: K562 cell lysate (20 µg)
Lane 4: HepG2 cell lysate (20 µg)
Lanes 1 - 4: Merged signal (red and green). Green - ab75749 observed at 36 kDa. Red - loading control, ab18058, observed at 124 kDa.ab75749 was shown to specifically react with PACT (PKR activating protein)/PRKRA when PACT (PKR activating protein)/PRKRA knockout samples were used. Wild-type and PACT (PKR activating protein)/PRKRA knockout samples were subjected to SDS-PAGE. ab75749 and ab18058 (loading control to Vinculin) were diluted at 1/1000 and 1/10 000 respectively and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) ab216773 and Goat anti-Mouse IgG H&L (IRDye® 680RD) ab216776 secondary antibodies at 1/10 000 dilution for 1 h at room temperature before imaging.
-
All lanes : Anti-PACT (PKR activating protein) / PRKRA antibody [EPR3224] (ab75749) at 1/1000 dilution
Lane 1 : K562 cell lysate
Lane 2 : Jurkat cell lysate
Lane 3 : HepG2 cell lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 34 kDa
Observed band size: 34 kDa
数据表及文件
-
SDS download
-
Datasheet download
文献 (12)
ab75749 被引用在 12 文献中.
- Ye T et al. Large extracellular vesicles secreted by human iPSC-derived MSCs ameliorate tendinopathy via regulating macrophage heterogeneity. Bioact Mater 21:194-208 (2023). PubMed: 36101856
- Frederick K & Patel RC Luteolin protects DYT-PRKRA cells from apoptosis by suppressing PKR activation. Front Pharmacol 14:1118725 (2023). PubMed: 36874028
- Vaughn LS et al. DYT-PRKRA Mutation P222L Enhances PACT's Stimulatory Activity on Type I Interferon Induction. Biomolecules 12:N/A (2022). PubMed: 35625640
- Montavon TC et al. Human DICER helicase domain recruits PKR and modulates its antiviral activity. PLoS Pathog 17:e1009549 (2021). PubMed: 33984068
- Ukhueduan B et al. Regulation of PKR activation and apoptosis during oxidative stress by TRBP phosphorylation. Int J Biochem Cell Biol 137:106030 (2021). PubMed: 34174402